Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02211209
Study type Interventional
Source Ionis Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 3
Start date December 2014
Completion date March 28, 2017

See also
  Status Clinical Trial Phase
Completed NCT04223908 - InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia
Active, not recruiting NCT05130450 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) Phase 3
Completed NCT04568434 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) Phase 3
Completed NCT03912181 - Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes
Not yet recruiting NCT05902598 - A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome Phase 3
Active, not recruiting NCT05185843 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen Phase 3
Completed NCT02658175 - The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome Phase 3
Completed NCT03360747 - Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) Phase 2
Available NCT06360237 - Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)